Physician profile
Alexander Ende
NPI 1437477197
$6,782.89
in general payments reported to CMS, 2019-2025
28 companies · $1,301 in 2025
The $1,301 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $165 · 2021: $304 · 2022: $1,303 · 2023: $1,861 · 2024: $1,656 · 2025: $1,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,817.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,380.24 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $714.07 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $477.69 | 2020-2025 | Xifaxan |
| Janssen Biotech, INC. | $477.38 | 2023-2025 | Stelara, Tremfya, Remicade |
| Gilead Sciences, INC. | $424.55 | 2021-2025 | |
| Celgene Corporation | $295.42 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $261.54 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $255.95 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $228.11 | 2022-2025 | |
| Olympus America INC. | $203.12 | 2022 | |
| Qol Medical, LLC | $200.84 | 2021-2025 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $144.19 | 2019-2024 | Ocaliva |
| Regeneron Healthcare Solutions, INC. | $136.23 | 2022-2025 | Dupixent |
| Boston Scientific Corporation | $102.95 | 2025 | Resolution 360 Clip |
| Pfizer INC. | $93.35 | 2019-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $70.92 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $55.78 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $49.76 | 2023-2025 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.19 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $26.11 | 2020 | |
| Amgen INC. | $24.07 | 2023 | Avsola, Amjevita |
| Phathom Pharmaceuticals, INC. | $22.05 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $19.58 | 2025 | Zenpep |
| Allergan, INC. | $18.46 | 2019 | |
| Shionogi INC | $16.11 | 2019 | |
| Ethicon US, LLC | $15.08 | 2020 | |
| Mirum Pharmaceuticals, INC. | $14.93 | 2024 | Livmarli |
| Organon LLC | $13.22 | 2023 | Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Ende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.